Screener
Enliven Therapeutics ELVN Total Assets
Total Assets at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The source filing: Enliven Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211982
| Line item | As of / March 31, 2026 | As of / December 31, 2025 |
|---|---|---|
| Operating lease right-of-use assets | 290 | 383 |
| Deferred offering costs | 217 | 217 |
| Other long-term assets | 1,188 | 656 |
| Total assets | $464,852 | $476,168 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $1,640 | $2,159 |
| Accrued expenses and other current liabilities | 9,847 | 14,409 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Enliven Therapeutics's total assets?
- Enliven Therapeutics (ELVN) reported total assets of $464.85M in Q1 2026.
- How has Enliven Therapeutics's total assets changed year-over-year?
- Enliven Therapeutics's total assets increased by 53.6% year-over-year, from $302.57M to $464.85M.
- What is the long-term trend for Enliven Therapeutics's total assets?
- Over 5 years (2020 to 2025), Enliven Therapeutics's total assets has grown at a 39.3% compound annual growth rate (CAGR), from $90.84M to $476.17M.
- What does total assets mean?
- The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.
Ask your AI about Enliven Therapeutics's total assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude